WEKO3
アイテム
Prospective Study of Gefitinib Readministration After Chemotherapy in Patients With Advanced Non-Small-Cell Lung Cancer Who Previously Responded to Gefitinib
http://hdl.handle.net/10091/17596
http://hdl.handle.net/10091/1759687bd8a4c-e859-41bc-9f39-de76ed08a3e9
| 名前 / ファイル | ライセンス | アクション |
|---|---|---|
Prospective_study_gefitinib_readministration_after_chemotherapy.pdf (392.4 kB)
|
|
| Item type | 学術雑誌論文 / Journal Article(1) | |||||
|---|---|---|---|---|---|---|
| 公開日 | 2014-06-12 | |||||
| タイトル | ||||||
| タイトル | Prospective Study of Gefitinib Readministration After Chemotherapy in Patients With Advanced Non-Small-Cell Lung Cancer Who Previously Responded to Gefitinib | |||||
| 言語 | en | |||||
| 言語 | ||||||
| 言語 | eng | |||||
| DOI | ||||||
| 識別子タイプ | DOI | |||||
| 関連識別子 | https://doi.org/10.1016/j.cllc.2012.01.006 | |||||
| 関連名称 | 10.1016/j.cllc.2012.01.006 | |||||
| キーワード | ||||||
| 主題Scheme | Other | |||||
| 主題 | Chemotherapy | |||||
| キーワード | ||||||
| 主題Scheme | Other | |||||
| 主題 | EGFR mutation | |||||
| キーワード | ||||||
| 主題Scheme | Other | |||||
| 主題 | Epidermal growth factor receptor tyrosine kinase inhibitor | |||||
| キーワード | ||||||
| 主題Scheme | Other | |||||
| 主題 | Gefitinib responder | |||||
| キーワード | ||||||
| 主題Scheme | Other | |||||
| 主題 | Non-small-cell lung cancer | |||||
| キーワード | ||||||
| 主題Scheme | Other | |||||
| 主題 | Recharrenge | |||||
| 資源タイプ | ||||||
| 資源タイプ識別子 | http://purl.org/coar/resource_type/c_6501 | |||||
| 資源タイプ | journal article | |||||
| 著者 |
Koizumi, Tomonobu
× Koizumi, Tomonobu× Agatsuma, Toshihiko× Ikegami, Kayoko× Suzuki, Toshiro× Kobayashi, Takashi× Kanda, Shintaro× Yoshikawa, Sumiko× Kubo, Keishi× Shiina, Takayuki× Takasuna, Keiichirou× Matsuo, Akemi× Hayasaka, Muneharu× Morikawa, Miwa× Ameshima, Shingo |
|||||
| 信州大学研究者総覧へのリンク | ||||||
| 表示名 | Koizumi, Tomonobu | |||||
| URL | http://soar-rd.shinshu-u.ac.jp/profile/ja.WakmHhkh.html | |||||
| 出版者 | ||||||
| 出版者 | CIG MEDIA GROUP, LP | |||||
| 引用 | ||||||
| 内容記述タイプ | Other | |||||
| 内容記述 | CLINICAL LUNG CANCER. 13(6):458-463 (2012) | |||||
| 書誌情報 |
CLINICAL LUNG CANCER 巻 13, 号 6, p. 458-463, 発行日 2012-11 |
|||||
| 抄録 | ||||||
| 内容記述タイプ | Abstract | |||||
| 内容記述 | The present study was designed to prospectively evaluate the clinical efficacy of gefitinib readministration in patients with advanced non-small cell lung cancer who responded well to initial gefitinib, followed by cytotoxic chemotherapy. Twenty subjects were enrolled, and 3 and 6 patients achieved partial response and stable disease, respectively. These findings provide valuable information for the management of previous gefitinib responders. Introduction: Salvage treatment for acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitor in patients with non-small-cell lung cancer is a matter of clinical concern. Several retrospective reports have indicated the usefulness of epidermal growth factor receptor tyrosine kinase inhibitor readministration; however, there have been few prospective studies. Materials and Methods: This study was designed to prospectively evaluate the clinical efficacy of gefitinib readministration in patients with advanced or metastatic non-small-cell lung cancer who responded well to initial gefitinib treatment. The subjects received at least 1 regimen of cytotoxic chemotherapy after progressive disease with the initial gefitinib therapy. Gefitinib administration (250 mg/d, orally) was started after progressive disease with the previous chemotherapeutic regimen. The primary endpoint in the present study was the response rate. Results: Twenty patients were enrolled between April 2007 and May 2011. Three patients achieved partial response, and 6 showed stable disease. Thus, the overall response rate and disease control rate of gefitinib readministration were 15% (95% Cl, 3.21-37.9) and 45% (95% Cl, 23.1-68.5), respectively. Median progression-free survival and overall survival from the start of gefitinib readministration were 2.0 months (95% Cl, 0.9-3.1 months) and 12.0 months (95% Cl, 8.0-16.0 months), respectively. Conclusion: These results suggest that gefitinib readministration may be an option, albeit with a low response rate and short progression-free survival, for patients who responded well to initial gefitinib followed by systemic chemotherapy. These findings provide valuable information for the management of previous gefitinib responders. | |||||
| 資源タイプ（コンテンツの種類） | ||||||
| 内容記述タイプ | Other | |||||
| 内容記述 | Article | |||||
| ISSN | ||||||
| 収録物識別子タイプ | PISSN | |||||
| 収録物識別子 | 1525-7304 | |||||
| 書誌レコードID | ||||||
| 収録物識別子タイプ | NCID | |||||
| 収録物識別子 | AA11973261 | |||||
| PubMed | ||||||
| 識別子タイプ | PMID | |||||
| 関連識別子 | https://pubmed.ncbi.nlm.nih.gov/22402083 | |||||
| 関連名称 | 22402083 | |||||
| 権利 | ||||||
| 権利情報 | Copyright© 2012 Elsevier | |||||
| 出版タイプ | ||||||
| 出版タイプ | AM | |||||
| 出版タイプResource | http://purl.org/coar/version/c_ab4af688f83e57aa | |||||
| WoS | ||||||
| 表示名 | Web of Science | |||||
| URL | http://gateway.isiknowledge.com/gateway/Gateway.cgi?&GWVersion=2&SrcAuth=ShinshuUniv&SrcApp=ShinshuUniv&DestLinkType=FullRecord&DestApp=WOS&KeyUT=000310411400008 | |||||
